跳转至内容
Merck
CN
  • Evaluation of a 2-pyridone, KRQ-10018, against Mycobacterium tuberculosis in vitro and in vivo.

Evaluation of a 2-pyridone, KRQ-10018, against Mycobacterium tuberculosis in vitro and in vivo.

Antimicrobial agents and chemotherapy (2008-02-13)
Anne J Lenaerts, Casey Bitting, Lisa Woolhiser, Veronica Gruppo, Karen S Marietta, Christine M Johnson, Ian M Orme
摘要

A novel subclass of quinolones, 2-pyridones, showed potent activity against Mycobacterium tuberculosis, with KRQ-10018 being an early lead. KRQ-10018 showed better activity in vitro against M. tuberculosis versus moxifloxacin. In vivo efficacy of KRQ-10018 at 300 mg/kg of body weight was similar to that of isoniazid at 25 mg/kg, but showed less activity than moxifloxacin at 300 mg/kg.

材料
产品编号
品牌
产品描述

Sigma-Aldrich
利福平, ≥95% (HPLC), powder or crystals
Sigma-Aldrich
环丙沙星, ≥98% (HPLC)
Sigma-Aldrich
利福平, suitable for plant cell culture, BioReagent, ≥95% (HPLC), powder or crystals
Supelco
异烟肼, analytical standard, ≥99% (TLC)
Supelco
环丙沙星, VETRANAL®, analytical standard